Literature DB >> 16868442

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy.

Gregory P Bisson1, Robert Gross, Jordan B Strom, Caitlin Rollins, Scarlett Bellamy, Rachel Weinstein, Harvey Friedman, Diana Dickinson, Ian Frank, Brian L Strom, Tendani Gaolathe, Ndwapi Ndwapi.   

Abstract

OBJECTIVE: To derive and internally validate a clinical prediction rule for virologic response based on CD4 cell count increase after initiation of HAART in a resource-limited setting. DESIGN AND METHODS: A retrospective cohort study at two HIV care clinics in Gaborone, Botswana. The participants were previously treatment-naive HIV-1-infected individuals initiating HAART. The main outcome measure was a plasma HIV-1 RNA level (viral load) < or = 400 copies/ml (i.e. undetectable) 6 months after initiating HAART.
RESULTS: The ability of CD4 cell count increase to predict an undetectable viral load was significantly better in those with baseline CD4 cell counts < or = 100 cells/microl [area under the ROC curve (AUC), 0.78; 95% confidence interval (CI), 0.67-0.89; versus AUC, 0.60; 95% CI, 0.48-0.71; P = 0.018]. The sensitivity, specificity, and positive and negative predictive values of a CD4 cell count increase of > or = 50 cells/microl for an undetectable viral load in those with baseline CD4 cell counts < or = 100 cells/microl were 93.1, 61.3, 92.5 and 63.3%, respectively. Alternatively, these values were 47.8, 87.1, 95.0 and 24.5%, respectively, if a increase in CD4 cell count of > or = 150 cells/microl was used.
CONCLUSIONS: CD4 cell count increase after initiating HAART has only moderate discriminative ability in identifying patients with an undetectable viral load, and the predictive ability is higher [corrected] in patients with lower baseline CD4 cell counts. Although HIV treatment programs in resource-constrained settings could consider the use of CD4 cell count increases to triage viral load testing, more accurate approaches to monitoring virologic failure are urgently needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16868442     DOI: 10.1097/01.aids.0000238407.00874.dc

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  29 in total

1.  Prediction based classification for longitudinal biomarkers.

Authors:  A S Foulkes; L Azzoni; X Li; M A Johnson; C Smith; K Mounzer; L J Montaner
Journal:  Ann Appl Stat       Date:  2010-09       Impact factor: 2.083

2.  Optimal Allocation of Gold Standard Testing under Constrained Availability: Application to Assessment of HIV Treatment Failure.

Authors:  Tao Liu; Joseph W Hogan; Lisa Wang; Shangxuan Zhang; Rami Kantor
Journal:  J Am Stat Assoc       Date:  2013-01-01       Impact factor: 5.033

3.  Mortality after failure of antiretroviral therapy in sub-Saharan Africa.

Authors:  Olivia Keiser; Hannock Tweya; Paula Braitstein; François Dabis; Patrick MacPhail; Andrew Boulle; Denis Nash; Robin Wood; Ruedi Lüthi; Martin W G Brinkhof; Mauro Schechter; Matthias Egger
Journal:  Trop Med Int Health       Date:  2009-12-09       Impact factor: 2.622

4.  Pooled nucleic acid testing to identify antiretroviral treatment failure during HIV infection.

Authors:  Susanne May; Anthony Gamst; Richard Haubrich; Constance Benson; Davey M Smith
Journal:  J Acquir Immune Defic Syndr       Date:  2010-02       Impact factor: 3.731

5.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

6.  The efficacy of a computerized assessment of medication adherence in active substance users.

Authors:  Howard Newville; James L Sorensen
Journal:  J Int Assoc Provid AIDS Care       Date:  2013-05-29

7.  Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy.

Authors:  Olivia Keiser; Patrick MacPhail; Andrew Boulle; Robin Wood; Mauro Schechter; François Dabis; Eduardo Sprinz; Matthias Egger
Journal:  Trop Med Int Health       Date:  2009-07-14       Impact factor: 2.622

8.  Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.

Authors:  Padmini Srikantiah; Maria N Walusimbi; H Kose Kayanja; Harriet Mayanja-Kizza; Roy D Mugerwa; Royce Lin; Edwin D Charlebois; W Henry Boom; Christopher C Whalen; Diane V Havlir
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

9.  Evaluation of Dynabeads and Cytospheres compared with flow cytometry to enumerate CD4+ T cells in HIV-infected Ugandans on antiretroviral therapy.

Authors:  Fred Lutwama; Ronnie Serwadda; Harriet Mayanja-Kizza; Hasan M Shihab; Allan Ronald; Moses R Kamya; David Thomas; Elizabeth Johnson; Thomas C Quinn; Richard D Moore; Lisa A Spacek
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

10.  Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay.

Authors:  Sumathi Sivapalasingam; Beatrice Wangechi; Fatuma Marshed; Maura Laverty; Shaffiq Essajee; Robert S Holzman; Fred Valentine
Journal:  PLoS One       Date:  2009-08-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.